First approved inhaled insulin therapy for diabetes mellitus (Q36690218)

15 August 2017

1 reference

title

First approved inhaled insulin therapy for diabetes mellitus (English)

1 reference

15 August 2017

1 reference

4

Ralph A Defronzo

1 reference

15 August 2017

Rucha Jani

1

1 reference

15 August 2017

Curtis Triplitt

series ordinal

2

1 reference

15 August 2017

Charles Reasner

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Drug Delivery

15 August 2017

1 reference

15 August 2017

4

1 reference

15 August 2017

1

1 reference

15 August 2017

63-76

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Association between glycemic state and lung function: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

The impact of smoking on inhaled insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Inhaled human insulin treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Pulmonary insulin administration using the AERx insulin diabetes system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Dose-Response Relationships of Inhaled Insulin Delivered via the Aerodose Insulin Inhaler and Subcutaneously Injected Insulin in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.4.1.63

21 January 2018

Identifiers

DOI

10.1517/17425247.4.1.63

1 reference

15 August 2017

1 reference